pI: 9.0731 |
Length (AA): 336 |
MW (Da): 39605 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
5 | 336 | 2zbk (A) | 10 | 389 | 24.00 | 0 | 1 | 1.2089 | 0.27 |
51 | 335 | 1d3y (A) | 72 | 368 | 22.00 | 0 | 1 | 1.07731 | -0.48 |
122 | 193 | 4ja2 (A) | 17 | 86 | 30.00 | 0.27 | 0.26 | 0.358186 | 1.33 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Female Gametocyte. | Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | intra-erythrocytic - 40 hs, Sporozoite, Male Gametocyte. | Otto TD Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs, intra-erythrocytic - 24 hs, intra-erythrocytic - 32 hs, intra-erythrocytic - 48 hs, Oocyst. | Otto TD Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | Ring. | Zanghi G |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Ortholog group members (OG5_127274)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G02820 | DNA topoisomerase 6 subunit A |
Arabidopsis thaliana | AT3G13170 | meiotic recombination protein SPO11-1 |
Arabidopsis thaliana | AT1G63990 | meiotic recombination protein SPO11-2 |
Brugia malayi | Bm1_31630 | Type IIB DNA topoisomerase family protein |
Candida albicans | CaO19.11071 | weak similarity to SPO11, catalytic subunit of topoisomerase-like transesterase involved in ds break formation step of meiotic r |
Candida albicans | CaO19.3589 | catalytic subunit of meiotic double strand break transesterase |
Caenorhabditis elegans | CELE_T05E11.4 | Protein SPO-11 |
Cryptosporidium hominis | Chro.80160 | SPO11 protein |
Cryptosporidium parvum | cgd8_1350 | topoisomerase VIA/SpoII nuclease subunit, toprim domain |
Cryptosporidium parvum | cgd3_2720 | putative topoisomerase VIA |
Drosophila melanogaster | Dmel_CG7753 | meiotic W68 |
Echinococcus granulosus | EgrG_000831500 | meiotic recombination protein SPO11 |
Entamoeba histolytica | EHI_194510 | DNA topoisomerase, putative |
Entamoeba histolytica | EHI_125320 | topoisomerase, putative |
Echinococcus multilocularis | EmuJ_000831500 | meiotic recombination protein SPO11 |
Giardia lamblia | GL50803_15279 | Spo11 Type II DNA topoisomerase VI subunit A |
Homo sapiens | ENSG00000054796 | SPO11 meiotic protein covalently bound to DSB |
Leishmania braziliensis | LbrM.16.0620 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_160630.1 | meiotic recombination protein SPO11, putative |
Leishmania infantum | LinJ.16.0630 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_10673 | type IIB DNA topoisomerase |
Mus musculus | ENSMUSG00000005883 | SPO11 meiotic protein covalently bound to DSB homolog (S. cerevisiae) |
Oryza sativa | 9267055 | Os03g0752200 |
Oryza sativa | 4344697 | Os08g0156900 |
Oryza sativa | 4332470 | Os03g0284800 |
Oryza sativa | 4352826 | Os12g0622500 |
Plasmodium berghei | PBANKA_0511700 | topoisomerase, putative |
Plasmodium berghei | PBANKA_1432700 | meiotic recombination protein SPO11, putative |
Plasmodium falciparum | PF3D7_1217100 | meiotic recombination protein SPO11, putative |
Plasmodium falciparum | PF3D7_1027600 | topoisomerase, putative |
Plasmodium knowlesi | PKNH_1436700 | meiotic recombination protein SPO11, putative |
Plasmodium knowlesi | PKNH_0612000 | topoisomerase, putative |
Plasmodium vivax | PVX_123530 | meiotic recombination protein SPO11, putative |
Plasmodium vivax | PVX_111340 | hypothetical protein, conserved |
Plasmodium yoelii | PY05879 | putative topoisomerase VIA |
Saccharomyces cerevisiae | YHL022C | Spo11p |
Schistosoma japonicum | Sjp_0052550 | ko:K03166 DNA topoisomerase VI subunit A, putative |
Schistosoma mansoni | Smp_131670 | meiotic recombination protein spo11 |
Trypanosoma brucei gambiense | Tbg972.5.5230 | meiotic recombination protein spo11, putative |
Trypanosoma brucei | Tb927.5.3760 | meiotic recombination protein SPO11, putative |
Trypanosoma congolense | TcIL3000_0_05590 | meiotic recombination protein SPO11, putative |
Trypanosoma cruzi | TcCLB.511647.30 | meiotic recombination protein SPO11, putative |
Trypanosoma cruzi | TcCLB.503619.10 | meiotic recombination protein SPO11, putative |
Toxoplasma gondii | TGME49_240575 | type iib dna topoisomerase |
Theileria parva | TP04_0401 | hypothetical protein |
Trichomonas vaginalis | TVAG_258950 | meiosis-specific transesterase Spo11-1 |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.5.3760 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.5.3760 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.5.3760 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.5.3760 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_T05E11.4 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_T05E11.4 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_T05E11.4 | Caenorhabditis elegans | sterile | wormbase |
PBANKA_1432700 | Plasmodium berghei | Dispensable | plasmo |
TGME49_240575 | Toxoplasma gondii | Probably non-essential | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.